Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Modified-double Blind, Multi-center Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers (2 to 23 Months of Age) in China

NCT07710872 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT07710872
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07710872 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Modified-double Blind, Multi-center Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers (2 to 23 Months of Age) in China
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Recruiting
Start date
August 22, 2026
Completion date
July 26, 2029
Enrollment
4,568 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers, meningococcal infection